1. Market Research
  2. > Healthcare Market Trends
  3. > ViiV Healthcare Limited - Product Pipeline Review - 2013

ViiV Healthcare Limited - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

ViiV Healthcare Limited - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “ViiV Healthcare Limited - Product Pipeline Review - 2013” provides data on the ViiV Healthcare Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ViiV Healthcare Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from ViiV Healthcare Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ViiV Healthcare Limited - Brief ViiV Healthcare Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ViiV Healthcare Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ViiV Healthcare Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ViiV Healthcare Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ViiV Healthcare Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ViiV Healthcare Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ViiV Healthcare Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ViiV Healthcare Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ViiV Healthcare Limited and identify potential opportunities in those areas.

Table Of Contents

ViiV Healthcare Limited - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
ViiV Healthcare Limited Snapshot 4
ViiV Healthcare Limited Overview 4
Key Information 4
Key Facts 4
ViiV Healthcare Limited - Research and Development Overview 5
Key Therapeutic Areas 5
ViiV Healthcare Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
ViiV Healthcare Limited - Pipeline Products Glance 10
ViiV Healthcare Limited - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
ViiV Healthcare Limited - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
ViiV Healthcare Limited - Drug Profiles 12
(dolutegravir + abacavir sulphate + lamivudine) 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
dolutegravir 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
S/GSK-1265744 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
ViiV Healthcare Limited - Pipeline Analysis 18
ViiV Healthcare Limited - Pipeline Products by Therapeutic Class 18
ViiV Healthcare Limited - Pipeline Products by Target 19
ViiV Healthcare Limited - Pipeline Products by Route of Administration 20
ViiV Healthcare Limited - Pipeline Products by Molecule Type 21
ViiV Healthcare Limited - Pipeline Products by Mechanism of Action 22
ViiV Healthcare Limited - Recent Pipeline Updates 23
ViiV Healthcare Limited - Dormant Projects 27
ViiV Healthcare Limited - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
lersivirine 28
ViiV Healthcare Limited - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31



List of Tables

ViiV Healthcare Limited, Key Information 4
ViiV Healthcare Limited, Key Facts 4
ViiV Healthcare Limited - Pipeline by Indication, 2013 6
ViiV Healthcare Limited - Pipeline by Stage of Development, 2013 7
ViiV Healthcare Limited - Monotherapy Products in Pipeline, 2013 8
ViiV Healthcare Limited - Combination Treatment Modalities in Pipeline, 2013 9
ViiV Healthcare Limited - Pre-Registration, 2013 10
ViiV Healthcare Limited - Phase II, 2013 11
ViiV Healthcare Limited - Pipeline by Therapeutic Class, 2013 18
ViiV Healthcare Limited - Pipeline by Target, 2013 19
ViiV Healthcare Limited - Pipeline by Route of Administration, 2013 20
ViiV Healthcare Limited - Pipeline by Molecule Type, 2013 21
ViiV Healthcare Limited - Pipeline Products by Mechanism of Action, 2013 22
ViiV Healthcare Limited - Recent Pipeline Updates, 2013 23
ViiV Healthcare Limited - Dormant Developmental Projects,2013 27
ViiV Healthcare Limited - Discontinued Pipeline Products, 2013 28
ViiV Healthcare Limited, Other Locations 29



List of Figures

ViiV Healthcare Limited - Pipeline by Top 10 Indication, 2013 6
ViiV Healthcare Limited - Pipeline by Stage of Development, 2013 7
ViiV Healthcare Limited - Monotherapy Products in Pipeline, 2013 8
ViiV Healthcare Limited - Pipeline by Top 10 Therapeutic Class, 2013 18
ViiV Healthcare Limited - Pipeline by Top 10 Target, 2013 19
ViiV Healthcare Limited - Pipeline by Top 10 Route of Administration, 2013 20
ViiV Healthcare Limited - Pipeline by Top 10 Molecule Type, 2013 21
ViiV Healthcare Limited - Pipeline Products by Top 10 Mechanism of Action, 2013 22



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hyperlipidemia - Pipeline Review, H2 2016

Hyperlipidemia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Hyperlipidemia - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hyperlipidemia - Pipeline Review, H2 2016’, provides an overview of the Hyperlipidemia pipeline landscape. The report provides ...

Tetanus - Pipeline Review, H2 2016

Tetanus - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Tetanus - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tetanus - Pipeline Review, H2 2016’, provides an overview of the Tetanus pipeline landscape. The report provides comprehensive ...

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016’, provides an overview ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.